Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, PEG-MGF is used experimentally to enhance muscle repair and hypertrophy after mechanical overload or injury by stimulating satellite-cell activation and protein synthesis6373138.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, PEG-MGF is a poly(ethylene glycol)-conjugated form of Mechano Growth Factor (IGF-1Ec splice variant) comprising the 24-aa C-terminal E-peptide of IGF-1, designed to extend half-life while activating IGF-1 receptor–mediated anabolic signaling in muscle satellite cells637322138.
Liraglutide is 31 amino acids long, whereas PEG-MGF is shorter as it has a length of 24 amino acids. Liraglutide is made up of a sequence of sequence data not available in the current dataset. PEG-MGF is made up of a sequence of Tyrosine, Glutamine, Proline, Proline, Serine, Threonine, Asparagine, Lysine, Asparagine, Threonine, Lysine, Serine, Glutamine, Arginine, Arginine, Lysine, Glycine, Serine, Threonine, Phenylalanine, Glutamic acid, Glutamic acid, Arginine, Lysine.
Liraglutide
GCG
PEG-MGF
IGF1